Eletriptan Hydrobromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317767

CAS#: 177834-92-3

Description: Eletriptan Hydrobromide is a triptan with specific affinity for the 5-hydroxytriptamine1B/1D receptor. Eletriptan hydrobromide binds to and acts at serotonin 5-HT1B receptors located on intracranial blood vessels which leads to vasoconstriction. This drug may also exert its effects by binding to and activating 5-HT 1D receptors on sensory nerve endings in the trigeminal system, which results in the inhibition of pro-inflammatory neuropeptide release. Eletriptan hydrobromide is used to relieve pain or symptoms associated with migraine headaches.

Chemical Structure

img
Eletriptan Hydrobromide
CAS# 177834-92-3
Instruction

Theoretical Analysis

MedKoo Cat#: 317767
Name: Eletriptan Hydrobromide
CAS#: 177834-92-3
Chemical Formula: C22H27BrN2O2S
Exact Mass: 0.00
Molecular Weight: 463.430
Elemental Analysis: C, 57.02; H, 5.87; Br, 17.24; N, 6.04; O, 6.90; S, 6.92

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Eletriptan Hydrobromide; CHEBI:61176; M41W832TA3; UNII-M41W832TA3; eletriptan hydrobromide; Relpax; UK 166,044; UK 166044; UK-166,044; UK-166044;

IUPAC/Chemical Name: 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole;hydrobromide

InChi Key: UTINOWOSWSPFLJ-FSRHSHDFSA-N

InChi Code: InChI=1S/C22H26N2O2S.BrH/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20;/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3;1H/t19-;/m1./s1

SMILES Code: CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 463.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Madasu SB, Vekariya NA, Kiran MN, Gupta B, Islam A, Douglas PS, Babu KR.
Synthesis of compounds related to the anti-migraine drug eletriptan hydrobromide.
Beilstein J Org Chem. 2012;8:1400-5. Epub 2012 Aug 30. PubMed PMID: 23019477;
PubMed Central PMCID: PMC3458767.


2: Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and
pain-free nonresponders to treatment of the first attack: a pooled post-hoc
analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014
Apr;34(5):376-81. doi: 10.1177/0333102413512035. Epub 2013 Nov 21. PubMed PMID:
24265285.


3: Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E. A review of the
pharmacoeconomics of eletriptan for the acute treatment of migraine. Int J Gen
Med. 2015 Jan 12;8:27-36. doi: 10.2147/IJGM.S73673. eCollection 2015. Review.
PubMed PMID: 25624770; PubMed Central PMCID: PMC4296958.


4: Kertesz DP, Trabekin O, Vanetik MS. Headache treatment after electroconvulsive
treatment: a single-blinded trial comparator between eletriptan and paracetamol.
J ECT. 2015 Jun;31(2):105-9. doi: 10.1097/YCT.0000000000000179. PubMed PMID:
25181019.


5: Bhambri R, Martin VT, Abdulsattar Y, Silberstein S, Almas M, Chatterjee A,
Ramos E. Comparing the efficacy of eletriptan for migraine in women during
menstrual and non-menstrual time periods: a pooled analysis of randomized
controlled trials. Headache. 2014 Feb;54(2):343-54. doi: 10.1111/head.12257. Epub
2013 Oct 29. PubMed PMID: 24256184.


6: Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E. Consistency of eletriptan
in treating migraine: Results of a randomized, within-patient multiple-dose
study. Cephalalgia. 2014 Feb;34(2):126-35. doi: 10.1177/0333102413500726. Epub
2013 Aug 14. PubMed PMID: 23946318.


7: Dias A, Franco E, Hebert K, Mercedes A. Myocardial infarction after taking
eletriptan. Rev Port Cardiol. 2014 Jul-Aug;33(7-8):475.e1-3. doi:
10.1016/j.repc.2014.03.005. Epub 2014 Aug 23. English, Portuguese. PubMed PMID:
25155004.


8: Jocić B, Zecević M, Zivanović L, Protić A, Jadranin M, Vajs V. Study of forced
degradation behavior of eletriptan hydrobromide by LC and LC-MS and development
of stability-indicating method. J Pharm Biomed Anal. 2009 Nov 1;50(4):622-9. doi:
10.1016/j.jpba.2009.01.034. Epub 2009 Feb 6. PubMed PMID: 19250786.


9: Yilmaz H, Kaya M, Ozbek M, Delibasi T. A case of hyperprolactinemia, probably
induced by eletriptan. Int J Clin Pharmacol Ther. 2012 Dec;50(12):907-8. doi:
10.5414/CP201744. PubMed PMID: 22943929.


10: Ponnuru VS, Challa BR, Nadendla R. Quantitative analysis of eletriptan in
human plasma by HPLC-MS/MS and its application to pharmacokinetic study. Anal
Bioanal Chem. 2011 Nov;401(8):2539-48. doi: 10.1007/s00216-011-5341-4. Epub 2011
Sep 3. PubMed PMID: 21892641.


11: Marcus DA, Bernstein CD, Sullivan EA, Rudy TE. Perimenstrual eletriptan
prevents menstrual migraine: an open-label study. Headache. 2010
Apr;50(4):551-62. doi: 10.1111/j.1526-4610.2010.01628.x. Epub 2010 Mar 2. PubMed
PMID: 20236337.


12: Sandrini G, Perrotta A, Tassorelli C, Nappi G. Eletriptan. Expert Opin Drug
Metab Toxicol. 2009 Dec;5(12):1587-98. doi: 10.1517/17425250903410226. Review.
PubMed PMID: 19929447.


13: Sakai Y, Nishikawa M, Diksic M, Aubé M. α-[11C] methyl-L tryptophan-PET as a
surrogate for interictal cerebral serotonin synthesis in migraine without aura.
Cephalalgia. 2014 Mar;34(3):165-73. doi: 10.1177/0333102413506126. Epub 2013 Sep
20. PubMed PMID: 24057438.


14: Pascual J, Leira R, Lainez JM, Liaño H, Díez-Tejedor E, Navarro A, Jiménez D,
Ezpeleta D, Mateos V, Madrigal M, Palacios G; Grupo de Investigadores con
Eletriptán en España. [Spanish contribution to the clinical development of
eletriptan: an analysis of controlled studies]. Neurologia. 2004 Oct;19(8):414-9.
Spanish. PubMed PMID: 15470580.


15: Sheftell F, Ryan R, Pitman V; Eletriptan Steering Committee. Efficacy,
safety, and tolerability of oral eletriptan for treatment of acute migraine: a
multicenter, double-blind, placebo-controlled study conducted in the United
States. Headache. 2003 Mar;43(3):202-13. PubMed PMID: 12603638.


16: Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S; Eletriptan Steering
Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled,
multiple migraine attack study. Neurology. 2002 Oct 22;59(8):1210-7. PubMed PMID:
12391349.


17: Stark R, Dahlöf C, Haughie S, Hettiarachchi J; Eletriptan Steering Committee.
Efficacy, safety and tolerability of oral eletriptan in the acute treatment of
migraine: results of a phase III, multicentre, placebo-controlled study across
three attacks. Cephalalgia. 2002 Feb;22(1):23-32. PubMed PMID: 11993610.


18: Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ; Eletriptan
and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral
eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of
migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
Eur Neurol. 2002;47(2):99-107. PubMed PMID: 11844898.


19: Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for
the acute treatment of migraine in adolescents: results of a double-blind,
placebo-controlled trial. Headache. 2007 Apr;47(4):511-8. PubMed PMID: 17445100.


20: McCormack PL, Keating GM. Eletriptan: a review of its use in the acute
treatment of migraine. Drugs. 2006;66(8):1129-49. Review. PubMed PMID: 16789799.